RESUMO
PURPOSE: The purpose of this study was to evaluate acute effects of coffee with a high content of chlorogenic acids and different hydroxyhydroquinone contents on postprandial endothelial dysfunction. METHODS: This was a single-blind, randomized, placebo-controlled, crossover-within-subject clinical trial. A total of 37 patients with borderline or stage 1 hypertension were randomized to two study groups. The participants consumed a test meal with a single intake of the test coffee. Subjects in the Study 1 group were randomized to single intake of coffee with a high content of chlorogenic acids and low content of hydroxyhydroquinone or coffee with a high content of chlorogenic acids and a high content of hydroxyhydroquinone with crossover. Subjects in the Study 2 group were randomized to single intake of coffee with a high content of chlorogenic acids and low content of hydroxyhydroquinone or placebo coffee with crossover. Endothelial function assessed by flow-mediated vasodilation and plasma concentration of 8-isoprostanes were measured at baseline and at 1 and 2 h after coffee intake. RESULTS: Compared with baseline values, single intake of coffee with a high content of chlorogenic acids and low content of hydroxyhydroquinone, but not coffee with a high content of chlorogenic acids and high content of hydroxyhydroquinone or placebo coffee, significantly improved postprandial flow-mediated vasodilation and decreased circulating 8-isoprostane levels. CONCLUSIONS: These findings suggest that a single intake of coffee with a high content of chlorogenic acids and low content of hydroxyhydroquinone is effective for improving postprandial endothelial dysfunction. CLINICAL TRIAL REGISTRATION: URL for Clinical Trial: https://upload.umin.ac.jp ; Registration Number for Clinical Trial: UMIN000013283.
Assuntos
Ácido Clorogênico/farmacologia , Café , Endotélio Vascular/efeitos dos fármacos , Hidroquinonas/farmacologia , Hipertensão/dietoterapia , Estudos Cross-Over , Endotélio Vascular/fisiopatologia , Feminino , Humanos , Hipertensão/fisiopatologia , Masculino , Pessoa de Meia-Idade , Período Pós-Prandial , Método Simples-CegoRESUMO
Residual risk of cardiovascular disease might stem, at least partially, from low serum concentrations of n-3 polyunsaturated fatty acid (PUFA). The purpose of this study was to evaluate the effects of ezetimibe on serum lipids and PU-FAs in patients with coronary artery disease who were intolerant of new or high-dose statin therapy. The study population consisted of 13 patients who were intolerant of new statin therapy and 10 patients who were intolerant of high-dose statin therapy for the treatment of low-density lipoprotein (LDL) cholesterol. Patients who were intolerant of high-dose statin therapy continued taking a statin, but at a lower dose during the study period. Blood samples were collected before and 12 weeks after ezetimibe (10 mg). We measured serum lipids and PUFAs including dihomo-γ-linolenic acid, arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid. Ezetimibe significantly decreased LDL cholesterol (138 ± 19 mg/dL to 97 ± 34 mg/dL, P < 0.01), but did not significantly affect high-density lipoprotein cholesterol, triglyceride, or any of the PUFAs measured during the follow-up period. Consequently, it did not affect the ratio of EPA to AA (0.40 ± 0.17 to 0.43 ± 0.18, P = ns) or the ratio of n-3 PUFA to n-6 PUFA (1.10 ± 0.39 to 1.09 ± 0.36, P = ns) during the follow-up period. Ezetimibe in combination with a low-dose statin, or as monotherapy in statin-intolerant patients, decreased LDL cholesterol, but did not significantly affect serum PUFA concentrations in patients with coronary artery disease.
Assuntos
Anticolesterolemiantes/uso terapêutico , Azetidinas/uso terapêutico , Doença da Artéria Coronariana/sangue , Doença da Artéria Coronariana/tratamento farmacológico , Ácidos Graxos Insaturados/sangue , Idoso , Idoso de 80 Anos ou mais , Anticolesterolemiantes/sangue , Azetidinas/sangue , Ezetimiba , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
This report describes a case of atrioventricular crosstalk during a stimulation threshold test. This phenomenon was likely due to the accidental connection between the atrial and ventricular stylets. Electrocardiologists should recognize atrioventricular crosstalk during a stimulation threshold test to avoid repositioning the atrial lead unnecessarily or inducing ventricular arrhythmia.
Assuntos
Acidentes , Estimulação Cardíaca Artificial/efeitos adversos , Erros Médicos , Marca-Passo Artificial , Síndrome do Nó Sinusal/terapia , Idoso , Eletrocardiografia , Técnicas Eletrofisiológicas Cardíacas , Desenho de Equipamento , Átrios do Coração/fisiopatologia , Ventrículos do Coração/fisiopatologia , Humanos , Masculino , Limiar Sensorial , Síndrome do Nó Sinusal/fisiopatologiaAssuntos
Ácido Glicirrízico/toxicidade , Hipopotassemia/induzido quimicamente , Excipientes Farmacêuticos/toxicidade , Fitoterapia/efeitos adversos , Idoso , Idoso de 80 Anos ou mais , Aldosterona/sangue , Feminino , Humanos , Hipopotassemia/sangue , Hipopotassemia/diagnóstico , Japão , Masculino , Potássio/sangue , Renina/sangueRESUMO
A 26-year-old man was admitted to our hospital because of acute pericarditis. The current patient had a saddle-back type ST-segment elevation shortly after the onset of acute pericarditis. Interestingly, it converted into a coved type ST-segment elevation, subsequently regressed gradually as acute inflammation improved. After 3 months, right ventricular rapid pacing induced ventricular fibrillation, and intravenous sodium channel blocker induced a coved type ST-segment elevation. The current case implies that a Brugada-type ST-segment elevation, which is thought to be false in acute pericarditis, may be true in some patients with asymptomatic Brugada syndrome.